Volume 29 | January 8, 2025
As we step into 2025, we are inspired by the incredible strength and dedication of the osteosarcoma community. At MIB Agents, we believe that collaboration is the key to progress. Whether you're a scientist pushing the boundaries of research, a doctor providing life-saving care, a patient or family navigating the journey, an advocate raising awareness, an industry leader driving innovation, or a donor fueling hope—your role is vital. We invite you to join us—whether by sharing your insights, participating in events, supporting programs, or sparking new ideas. Together, we can make 2025 a year of unity, progress, and hope.
With hope,
The MIB Agents Team
.png)
We hope to see you in Salt Lake City in June! There's still time to submit an abstract for our FACTOR 2025 conference! Travel award applications will open next week and are due March 28, 2025. Stay tuned for registration details!
Submit an Abstract by January 10th
.png)
Share your story with our congressmen and women to advocate for several key policy issues that impact children with cancer. Join MIB Agents for Childhood Cancer Action Days on Capitol Hill, February 27-28th. Please contact Linda Kennington linda@mibagents.org for more information.
This month, we shine a spotlight on Dr. Nancy Gordon and her groundbreaking work at MD Anderson Cancer Center, where her lab delves into the biology of osteosarcoma. With a career shaped by a deep connection to her patients and a drive to bridge gaps between clinical care and research, Dr. Gordon has become a leading voice in pediatric oncology. From aerosolized therapies targeting pulmonary metastases to innovative approaches in NK cell therapy, her lab is tackling tough challenges in osteosarcoma treatment. We learn about Dr. Gordon’s journey, the pioneering projects of her lab, her vision for the future of osteosarcoma research, and how her passion and expertise are driving hope and progress for osteosarcoma patients.
Learn More About The Gordon Lab
- Director of Marketing - MIB Agents
- Pediatrics - Oncology Sarcoma (Professor), Baylor
- Pediatric Oncologist - Solid Tumor/Sarcoma Physician - U of Utah
- Medical Oncologist, Sarcoma - Montefiore Einstein
- Program Head, Sarcoma - Fred Hutchinson Cancer Center: Clinical Research Division
If you have a job posting and you would like it included here, please email christina@mibagents.org.
Check out the newly published 2025 NCCN Guidelines! We’re proud to share that MIB Agents' founder, Ann Graham, played a key role as a reviewer on the NCCN Bone Tumor Panel. These guidelines, crafted by top U.S. cancer centers, offer expert, evidence-based treatment recommendations to ensure the best care. Plus, the NCCN Guidelines for Patients break it down into easy-to-understand insights for patients and caregivers.
Download the 2025 NCCN Bone Cancer Guidelines
- Stakeholder Perspectives on Randomized Clinical Trials for Children With Poor-Prognosis Cancers
- New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers
- Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma
- Targeting RBM39 suppresses tumor growth and sensitizes osteosarcoma cells to cisplatin
- Genetic Variants Influence the Severity of Oral Mucositis in Pediatric Osteosarcoma Patients
- Machine learning uncovers three osteosarcoma subtypes for targeted treatment
- Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development
- Plasma microRNA signatures predict prognosis in canine osteosarcoma patients
Apply for the MIB Junior Advisory Board
SPAGN conducted a survey to better understand diagnosis pathways for patients. Preliminary results were shared at CTOS 2024. Some early insights:
- The median time from symptom onset to a correct diagnosis exceeds 3 months across the whole patient population, with some patients waiting up to 20 years for their diagnosis.
- Misdiagnoses are prevalent at 22% across all patient groups, with the 30–44 age group reporting the highest rate at 31%.
The survey closed on December 31st - stay tuned for more insights!
.png)
